Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review

Rachel A. Egler, Yasmin Gosiengfiao, Heidi Russell, Jonathan E. Wickiser, A. Lindsay Frazier

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sacrococcygeal teratoma (SCT) is the most common germ cell tumor (GCT) of infancy. Up to 35% of infants may have malignant elements. The standard of care for SCT with malignant elements (SCT-ME) has been surgery and chemotherapy. However, cases where low-stage SCT-ME have been successfully observed following resection have been reported. Procedure: To better understand the outcomes of low-stage SCT-ME that do not receive chemotherapy, we reviewed SCT pathology reports from five children's hospitals from 1999 to 2009. Information regarding staging workup, tumor markers, treatment, and outcome was collected for patients with stage I or II SCT-ME. An English language literature review was also performed. Results: Seventy-four SCT were identified: 51 stage I and 23 stage II; 13 (18%) were SCT-ME: 5 stage I and 8 stage II; four stage I and four stage II tumors were not treated with chemotherapy. No stage I tumors recurred; all of the stage II tumors recurred and were successfully salvaged, two had no ME at recurrence. We identified another 10 stage I SCT-ME in the literature managed with active surveillance-two recurred and were successfully treated with surgery and chemotherapy. Conclusions: Overall, of the 14 cases of stage I SCT-ME, 12 survived with no recurrence and the two who did recur were successfully treated with platinum-based chemotherapy (EFS = 86%, overall survival [OS] = 100%); this suggests that patients with stage I SCT-ME could be observed after surgery and treated only upon recurrence. Stage II SCT-ME require further study in a clinical trial setting.

Original languageEnglish (US)
JournalPediatric Blood and Cancer
DOIs
StateAccepted/In press - 2016

Fingerprint

Germ Cell and Embryonal Neoplasms
Teratoma
Observation
Drug Therapy
Recurrence
Neoplasms
Standard of Care
Tumor Biomarkers
Platinum
Language
Clinical Trials
Pathology

Keywords

  • Germ cell tumor
  • Sacrococcygeal teratoma
  • Surveillance

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review. / Egler, Rachel A.; Gosiengfiao, Yasmin; Russell, Heidi; Wickiser, Jonathan E.; Frazier, A. Lindsay.

In: Pediatric Blood and Cancer, 2016.

Research output: Contribution to journalArticle

@article{80d78f2211b847c986a56f494c2b5a33,
title = "Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review",
abstract = "Background: Sacrococcygeal teratoma (SCT) is the most common germ cell tumor (GCT) of infancy. Up to 35{\%} of infants may have malignant elements. The standard of care for SCT with malignant elements (SCT-ME) has been surgery and chemotherapy. However, cases where low-stage SCT-ME have been successfully observed following resection have been reported. Procedure: To better understand the outcomes of low-stage SCT-ME that do not receive chemotherapy, we reviewed SCT pathology reports from five children's hospitals from 1999 to 2009. Information regarding staging workup, tumor markers, treatment, and outcome was collected for patients with stage I or II SCT-ME. An English language literature review was also performed. Results: Seventy-four SCT were identified: 51 stage I and 23 stage II; 13 (18{\%}) were SCT-ME: 5 stage I and 8 stage II; four stage I and four stage II tumors were not treated with chemotherapy. No stage I tumors recurred; all of the stage II tumors recurred and were successfully salvaged, two had no ME at recurrence. We identified another 10 stage I SCT-ME in the literature managed with active surveillance-two recurred and were successfully treated with surgery and chemotherapy. Conclusions: Overall, of the 14 cases of stage I SCT-ME, 12 survived with no recurrence and the two who did recur were successfully treated with platinum-based chemotherapy (EFS = 86{\%}, overall survival [OS] = 100{\%}); this suggests that patients with stage I SCT-ME could be observed after surgery and treated only upon recurrence. Stage II SCT-ME require further study in a clinical trial setting.",
keywords = "Germ cell tumor, Sacrococcygeal teratoma, Surveillance",
author = "Egler, {Rachel A.} and Yasmin Gosiengfiao and Heidi Russell and Wickiser, {Jonathan E.} and Frazier, {A. Lindsay}",
year = "2016",
doi = "10.1002/pbc.26311",
language = "English (US)",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Is surgical resection and observation sufficient for stage I and II sacrococcygeal germ cell tumors? A case series and review

AU - Egler, Rachel A.

AU - Gosiengfiao, Yasmin

AU - Russell, Heidi

AU - Wickiser, Jonathan E.

AU - Frazier, A. Lindsay

PY - 2016

Y1 - 2016

N2 - Background: Sacrococcygeal teratoma (SCT) is the most common germ cell tumor (GCT) of infancy. Up to 35% of infants may have malignant elements. The standard of care for SCT with malignant elements (SCT-ME) has been surgery and chemotherapy. However, cases where low-stage SCT-ME have been successfully observed following resection have been reported. Procedure: To better understand the outcomes of low-stage SCT-ME that do not receive chemotherapy, we reviewed SCT pathology reports from five children's hospitals from 1999 to 2009. Information regarding staging workup, tumor markers, treatment, and outcome was collected for patients with stage I or II SCT-ME. An English language literature review was also performed. Results: Seventy-four SCT were identified: 51 stage I and 23 stage II; 13 (18%) were SCT-ME: 5 stage I and 8 stage II; four stage I and four stage II tumors were not treated with chemotherapy. No stage I tumors recurred; all of the stage II tumors recurred and were successfully salvaged, two had no ME at recurrence. We identified another 10 stage I SCT-ME in the literature managed with active surveillance-two recurred and were successfully treated with surgery and chemotherapy. Conclusions: Overall, of the 14 cases of stage I SCT-ME, 12 survived with no recurrence and the two who did recur were successfully treated with platinum-based chemotherapy (EFS = 86%, overall survival [OS] = 100%); this suggests that patients with stage I SCT-ME could be observed after surgery and treated only upon recurrence. Stage II SCT-ME require further study in a clinical trial setting.

AB - Background: Sacrococcygeal teratoma (SCT) is the most common germ cell tumor (GCT) of infancy. Up to 35% of infants may have malignant elements. The standard of care for SCT with malignant elements (SCT-ME) has been surgery and chemotherapy. However, cases where low-stage SCT-ME have been successfully observed following resection have been reported. Procedure: To better understand the outcomes of low-stage SCT-ME that do not receive chemotherapy, we reviewed SCT pathology reports from five children's hospitals from 1999 to 2009. Information regarding staging workup, tumor markers, treatment, and outcome was collected for patients with stage I or II SCT-ME. An English language literature review was also performed. Results: Seventy-four SCT were identified: 51 stage I and 23 stage II; 13 (18%) were SCT-ME: 5 stage I and 8 stage II; four stage I and four stage II tumors were not treated with chemotherapy. No stage I tumors recurred; all of the stage II tumors recurred and were successfully salvaged, two had no ME at recurrence. We identified another 10 stage I SCT-ME in the literature managed with active surveillance-two recurred and were successfully treated with surgery and chemotherapy. Conclusions: Overall, of the 14 cases of stage I SCT-ME, 12 survived with no recurrence and the two who did recur were successfully treated with platinum-based chemotherapy (EFS = 86%, overall survival [OS] = 100%); this suggests that patients with stage I SCT-ME could be observed after surgery and treated only upon recurrence. Stage II SCT-ME require further study in a clinical trial setting.

KW - Germ cell tumor

KW - Sacrococcygeal teratoma

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=84999622096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999622096&partnerID=8YFLogxK

U2 - 10.1002/pbc.26311

DO - 10.1002/pbc.26311

M3 - Article

C2 - 27786428

AN - SCOPUS:84999622096

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

ER -